Journal of Clinical Endocrinology & Metabolism最新文献

{"title":"Plasma levels of small HDL particles are associated with coronary atherosclerosis progression in adults with diabetes.","authors":"Bruna S B S Teles, Sergio H R Ramalho, Márcio S Bittencourt, Isabela M Benseñor, Michael J Blaha, Peter P Toth, Steven R Jones, Raul D Santos, Paulo A Lotufo, Luiz Sérgio F Carvalho","doi":"10.1210/clinem/dgaf215","DOIUrl":"https://doi.org/10.1210/clinem/dgaf215","url":null,"abstract":"<p><strong>Background: </strong>Type 2 diabetes mellitus (T2DM) is a major driver of coronary atherosclerosis progression, yet its impact is highly heterogeneous. Insulin resistance contributes to a complex interplay of metabolic disturbances that accelerate atherogenesis to varying degrees. Identifying biomarkers that refine cardiovascular risk prediction in this population remains a clinical priority.</p><p><strong>Objective: </strong>To evaluate the association between small HDL particle concentration and the incidence/progression of coronary artery calcium (CAC) in individuals with T2DM.</p><p><strong>Methods: </strong>We analyzed 4,331 participants from the ELSA-Brasil cohort. CAC incidence/progression was compared between individuals with and without T2DM. A subgroup of 461 non-statin users with T2DM and no baseline atherosclerotic cardiovascular disease (ASCVD) was further assessed for associations between small HDL particles (<8nm, HDLp1) and CAC outcomes.</p><p><strong>Results: </strong>Individuals with T2DM showed increased CAC incidence/progression rates compared to non-diabetic participants. Among 461 non-statin users with T2DM, 143 (31.0%) experienced CAC incidence/progression. Higher plasma concentrations of HDLp1 (3rd tertile) were associated with a 140% (95%CI 32-341%, p<0.001) greater likelihood of CAC incidence/progression compared to the 1st tertile. The inclusion of HDLp1 significantly improved CAC risk classification, with a net reclassification improvement (NRI) of 13.6% (95%CI 2.8-18.8%, p=0.004).</p><p><strong>Conclusion: </strong>HDLp1 concentration is significantly associated with CAC incidence/progression in individuals with T2DM and may improve risk discrimination for coronary atherosclerosis progression in this population.</p>","PeriodicalId":50238,"journal":{"name":"Journal of Clinical Endocrinology & Metabolism","volume":" ","pages":""},"PeriodicalIF":5.0,"publicationDate":"2025-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143774667","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Thyroid Hormone Sensitivity as a Possible Determinant of Metabolic Phenotypes in Young Adults, Not in the Elderly.","authors":"Min-Hee Kim, Jeongmin Lee, Dong-Jun Lim, Kyle Masato Ishikawa, James Davis, Eunjung Lim, Hyeong Jun Ahn","doi":"10.1210/clinem/dgaf214","DOIUrl":"https://doi.org/10.1210/clinem/dgaf214","url":null,"abstract":"<p><strong>Objective: </strong>We evaluated the association between thyroid sensitivity indices and metabolic phenotypes, including metabolically healthy and unhealthy individuals with obesity (MHO, MUO) and normal weight (MHNW, MUNW), focusing on age-specific differences.</p><p><strong>Methods: </strong>Data from participants aged ≥18 years in the National Health and Nutrition Examination Survey (NHANES) 2007-2012 were analyzed. Thyroid sensitivity indices, including the Thyroid Feedback Quantile-based Index (TFQI), Thyroid-Stimulating Hormone Index (TSHI), and Thyrotroph Thyroxine Resistance Index (TT4RI), were calculated. Multivariable regression and piecewise regression analyses were performed to examine associations between metabolic phenotypes and thyroid sensitivity indices, stratified by age groups (<65 and ≥65 years).</p><p><strong>Results: </strong>In the total population, the MUO group exhibited the significantly higher values for TSHI (p = 0.035) compared to the MHNW group, while there were borderline and no significant differences for TT4RI (p = 0.093) and TFQI (p = 0.134), respectively. Among younger adults (<65 years), MUO showed the highest values for TSHI (β = 0.122, p = 0.006), TT4RI (β = 2.006, p = 0.010), and TFQI (β = 0.058, p = 0.018), with significant linear and quadratic trends (p < 0.05). No significant associations were observed in older adults (≥65 years).</p><p><strong>Conclusions: </strong>Our findings highlight the importance of thyroid sensitivity indices in understanding metabolic health, particularly among younger adults. Incorporating these indices into clinical assessments may enhance metabolic phenotype stratification and inform targeted management of obesity.</p>","PeriodicalId":50238,"journal":{"name":"Journal of Clinical Endocrinology & Metabolism","volume":" ","pages":""},"PeriodicalIF":5.0,"publicationDate":"2025-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143781307","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Testosterone Effects on Short-Term Physical, Hormonal, and Neurodevelopmental Outcomes (TESTO) in Infants with 47,XXY.","authors":"Shanlee M Davis, Susan Howell, Jennifer Janusz, Najiba Lahlou, Regina Reynolds, Talia Thompson, Karli Swenson, Rebecca Wilson, Judith L Ross, Philip S Zeitler, Nicole R Tartaglia","doi":"10.1210/clinem/dgaf217","DOIUrl":"https://doi.org/10.1210/clinem/dgaf217","url":null,"abstract":"<p><strong>Context: </strong>47,XXY/Klinefelter syndrome (XXY) is associated with impaired testicular function and differences in physical growth, metabolism, and neurodevelopment. Clinical features of XXY may be influenced by testosterone during the mini-puberty period of infancy.</p><p><strong>Objective: </strong>We tested the hypothesis that exogenous testosterone treatment positively affects short-term physical, hormonal, and neurodevelopmental outcomes in infants with XXY.</p><p><strong>Design: </strong>Double-blind randomized controlled trial, 2017-2021.</p><p><strong>Setting: </strong>US tertiary care pediatric hospital.</p><p><strong>Patients: </strong>Infants 30-90 days of age with prenatally identified, non-mosaic 47,XXY (n=71).</p><p><strong>Intervention: </strong>Testosterone cypionate 25mg intramuscular injections every 4 weeks for 3 doses.</p><p><strong>Main outcome measures: </strong>The a priori primary outcomes were change in percent fat mass (%FM) z-scores and change in the total composite percentile on Alberta Infant Motor Scales (AIMS) assessment from baseline to 12 weeks.</p><p><strong>Results: </strong>The between group difference in change in %FM z-scores was -0.57 [95% CI -1.1, -0.06], p=0.03), secondary to greater increases in lean mass in the testosterone-treated group (1.5±0.4 kg vs 1.2±0.4, p=0.001). Testosterone suppressed gonadotropins and inhibin B (p<0.001 for all). In contrast, there were no significant group differences in short term motor, cognitive, or language outcomes (p>0.15 for all).</p><p><strong>Conclusions: </strong>In this double-blind randomized controlled trial in infants with XXY, testosterone injections resulted in physical effects attributable to systemic androgen exposure, however this dose suppressed the hypothalamic-pituitary-gonadal axis. Neurodevelopment outcomes were not impacted by treatment. These results do not support routine testosterone treatment in infants with XXY, however long term follow up on physical health, neurodevelopment and testicular function is needed.</p>","PeriodicalId":50238,"journal":{"name":"Journal of Clinical Endocrinology & Metabolism","volume":" ","pages":""},"PeriodicalIF":5.0,"publicationDate":"2025-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143774668","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to: \"Insulin Signaling Through the Insulin Receptor Increases Linear Growth Through Effects on Bone and the GH-IGF-1 Axis\".","authors":"","doi":"10.1210/clinem/dgaf186","DOIUrl":"https://doi.org/10.1210/clinem/dgaf186","url":null,"abstract":"","PeriodicalId":50238,"journal":{"name":"Journal of Clinical Endocrinology & Metabolism","volume":" ","pages":""},"PeriodicalIF":5.0,"publicationDate":"2025-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143774652","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessing the Cardiovascular Effects of Levothyroxine Use in an Ageing United Kingdom population (ACEL-UK): Cohort Study.","authors":"Mia Holley, Salman Razvi, Ian Maxwell, Rosie Dew, Scott Wilkes","doi":"10.1210/clinem/dgaf208","DOIUrl":"https://doi.org/10.1210/clinem/dgaf208","url":null,"abstract":"<p><strong>Context: </strong>Thyroid stimulating hormone (TSH) levels tend to rise with age, but standard reference intervals do not reflect this, potentially leading to overdiagnosis of subclinical hypothyroidism (SCH) and excessive levothyroxine (LT4) prescriptions in older adults.</p><p><strong>Methods: </strong>A retrospective cohort study was conducted utilising data from United Kingdom Primary Care patients from The Health Improvement Network, to compare outcomes in adults over 50 years with SCH who were either prescribed or not prescribed LT4. The primary outcome was cardiovascular events (angina, myocardial infarction, peripheral vascular disease, stent procedures, or stroke). Secondary outcomes included bone events (fragility fractures or osteoporosis) and all-cause mortality. Time-varying hazard ratios adjusted for relevant factors were estimated.</p><p><strong>Results: </strong>This study included 53,899 patients (baseline median age 67 years (IQR: 59-76); 68.5% female; median TSH 4.6mU/L (IQR: 4.1-5.4). Median follow-up duration was 10 years (IQR: 5.5-10.0). Of these, 19,952 (37%) received LT4 and 33,947 (63%) did not. LT4 therapy showed a protective effect against cardiovascular events (HR: 0.91; 95% CI: 0.87-0.97; p < 0.001) but increased risk of bone events (HR: 1.21; 95% CI: 1.14-1.28; p < 0.001) and all-cause mortality (HR: 1.17; 95% CI: 1.13-1.22; p < 0.001).</p><p><strong>Conclusions: </strong>Our data suggests that LT4 therapy in older individuals with SCH is associated with a trade-off between the potentially beneficial effect on cardiovascular risk and the deleterious relationship with bone health and mortality risk. These risks need to be considered, mitigated and discussed when LT4 therapy is being deliberated in older patients with SCH.</p>","PeriodicalId":50238,"journal":{"name":"Journal of Clinical Endocrinology & Metabolism","volume":" ","pages":""},"PeriodicalIF":5.0,"publicationDate":"2025-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143781303","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Characterizing Disparities in Access to Surgery for Pituitary Adenomas: A National Cancer Database Analysis.","authors":"Miguel Angel Jimenez, Melanie A Horowitz, Julian L Gendreau, Bakhtiar Yamini, A Karim Ahmed, Mathew Geltzeiler, Olabisi Sanusi, Eric W Wang, Carl H Snyderman, Garret W Choby, Georgios A Zenonos, Paul A Gardner, Nicholas R Rowan, Debraj Mukherjee","doi":"10.1210/clinem/dgaf212","DOIUrl":"https://doi.org/10.1210/clinem/dgaf212","url":null,"abstract":"<p><strong>Context: </strong>Although there is an established improved postoperative outcome for pituitary adenomas (PA) surgically resected at high-volume facilities (HVFs), access to these centers may not be equitable.</p><p><strong>Objective: </strong>To investigate the racial and socioeconomic differences that lead to unequal distribution of access for PAs at HVFs in the United States.</p><p><strong>Design and patients: </strong>Retrospective analysis of data from the National Cancer Database (NCDB) from 2004 to 2019 on 57,807 patients with PA.</p><p><strong>Main outcome measures: </strong>Baseline description of patients treated at HVFs, survival outcomes, and predictors of survival were evaluated in patients with PA.</p><p><strong>Results: </strong>A total of 47.6% (n = 27,523) underwent surgery at a HVF. On multivariable analysis, African-American race (OR: 0.89, p < 0.001) and Hispanic ethnicity (OR: 0.80, p < 0.001) had significantly lower odds of having a surgical procedure at a HVF, as compared to a reference Caucasian population. Patients from rural locations (OR: 0.79, p = 0.003; reference = urban); with Medicaid insurance (OR: 0.86, p < 0.001; reference = private); those with lower-income (< $40,227 [OR: 0.93, p = 0.049]; reference = ≥ $63,333); and patients from zip codes with large percentages of adults who did not graduate high school (≥ 17.6% [OR: 0.95, p < 0.001]; reference = < 6.3%) were significantly less likely to have surgery at a HVF. An increasing trend in access to surgical care at HVFs for PA patients over time was demonstrated (e. g., 2005 [OR = 1.10 (0.97-1.26, p = 0.173] vs. 2019 [OR = 1.27 (1.13-1.43), p < 0.001]).</p><p><strong>Conclusion: </strong>There is significant racial and socioeconomic disparities in access to HVFs for adult patients seeking surgical resection of pituitary adenomas.</p>","PeriodicalId":50238,"journal":{"name":"Journal of Clinical Endocrinology & Metabolism","volume":" ","pages":""},"PeriodicalIF":5.0,"publicationDate":"2025-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143765737","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Wake Up and Smell - the Cortisol?","authors":"Joanna L Spencer-Segal, Richard J Auchus","doi":"10.1210/clinem/dgaf197","DOIUrl":"https://doi.org/10.1210/clinem/dgaf197","url":null,"abstract":"","PeriodicalId":50238,"journal":{"name":"Journal of Clinical Endocrinology & Metabolism","volume":" ","pages":""},"PeriodicalIF":5.0,"publicationDate":"2025-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143765537","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A three-week Ketogenic Diet increases Global Cerebral Blood Flow and Brain-Derived Neurotrophic Factor.","authors":"Thien Vinh Luong, Kim Vang Hansen, Allan Kjeldsen Hansen, Stephen C Cunnane, Niels Møller, Esben Søndergaard, Lars Christian Gormsen, Mads Svart","doi":"10.1210/clinem/dgaf207","DOIUrl":"https://doi.org/10.1210/clinem/dgaf207","url":null,"abstract":"<p><strong>Purpose: </strong>The beneficial effects of a ketogenic diet (KD) on neurodegenerative conditions such as mild cognitive impairment (MCI) and Alzheimer's disease (AD) are increasingly acknowledged, with potential implications for the general population as well. Thus, our study aimed to explore the effect of a KD on cerebral blood flow (CBF) and Brain-Derived Neurotrophic Factor (BDNF) in healthy individuals. We hypothesized that a KD would increase CBF and BDNF, thereby presenting itself as an approach to prevent cognitive decline.</p><p><strong>Methods: </strong>In total, 11 cognitively healthy individuals with overweight participated in a randomized, crossover trial consisting of two three-week interventions: 1) a KD and 2) a standard diet. Each diet period concluded with a positron emission tomography (PET) study day, accompanied by a separate magnetic resonance imaging (MRI) scan. Blood samples were collected prior to the PET scan to measure β-hydroxybutyrate (β-OHB) and BDNF levels. CBF was assessed using a [15O]H2O PET scan co-registered with an MRI scan.</p><p><strong>Results: </strong>A KD led to increased basal plasma β-OHB levels compared to the SDD (647 (418-724) vs. 50 (50-60) μmol/l, p<0.05), increased CBF by 22% (p=0.02), and elevated BDNF levels by 47% (p=0.04). Moreover, a correlation was observed between β-OHB levels and CBF measurements across the two diets (R2=0.54, p<0.001).</p><p><strong>Conclusion: </strong>Implementing a KD improved CBF and raised BDNF levels in cognitively healthy individuals, indicating that a KD should be assessed for as a potential treatment for conditions associated with reduced CBF.</p>","PeriodicalId":50238,"journal":{"name":"Journal of Clinical Endocrinology & Metabolism","volume":" ","pages":""},"PeriodicalIF":5.0,"publicationDate":"2025-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143765707","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chronotherapy with Once-Daily Osilodrostat Improves Cortisol Rhythm, Quality of Life, and Sleep in Cushing's Syndrome.","authors":"Davide Ferrari, Ilaria Bonaventura, Chiara Simeoli, Alessandra Tomaselli, Ludovica Vincenzi, Dario De Alcubierre, Francesca Sciarra, Flavio Rizzo, Lorenzo Cerroni, Nicola Di Paola, Marianna Minnetti, Emilia Sbardella, Mary Anna Venneri, Riccardo Pofi, Rosario Pivonello, Daniele Gianfrilli, Valeria Hasenmajer, Andrea M Isidori","doi":"10.1210/clinem/dgaf206","DOIUrl":"https://doi.org/10.1210/clinem/dgaf206","url":null,"abstract":"<p><strong>Introduction: </strong>Medical therapy for Cushing's syndrome (CS) typically aims to reduce daily cortisol output without addressing circadian rhythm restoration. No licensed drugs target this objective. We investigated the efficacy and safety of timed, once-daily osilodrostat administration in improving circadian cortisol profiles in CS.</p><p><strong>Methods: </strong>A prospective, multicenter study evaluated patients with well-controlled CS on a stable twice-daily osilodrostat therapy before and 60-90 days after transitioning to a single equivalent daily dose at 19:00 ± 1 hour. Circadian steroid analysis was performed on saliva, serum, and urine using UHPLC-MS/MS. Additional assessments included cardio-metabolic markers, quality of life, sleep function, and safety outcomes.</p><p><strong>Results: </strong>Sixteen patients (4 males; 7 pituitary, mean age 53.3 ± 11.8 years) were enrolled. At baseline, CS was well-controlled with a mean osilodrostat dose of 4.2±1.3 mg. After transitioning, salivary cortisol exposure decreased significantly during the afternoon-to-early morning period [AUC16:00-08:00: -6.1 (-0.15 to -12.1) ng/mL/h, p = .029]. Quality of life and sleep improved (CushingQoL: +4.2, p = .029; PSQI: -1.7, p = .049). Serum steroid precursors, including 11-deoxycorticosterone (-3.1 ng/mL/h, p = .008) and 11-deoxycortisol (-17.8 ng/mL/h, p = .005), decreased. Eight patients advancing dosing to 16:00 ± 1 hour showed comparable reductions, with phase shifts in acrophase and nadir. No patients developed adrenal insufficiency, liver toxicity, ECG abnormalities, or loss of disease control.</p><p><strong>Conclusions: </strong>Once-daily osilodrostat effectively and safely treats patients with biochemically controlled CS, improving circadian cortisol profiles, quality of life, and sleep. Findings support further exploration of chronotherapy-based approaches in CS management.</p>","PeriodicalId":50238,"journal":{"name":"Journal of Clinical Endocrinology & Metabolism","volume":" ","pages":""},"PeriodicalIF":5.0,"publicationDate":"2025-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143765743","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Growth Hormone on Skeletal Muscle Strength, Power, Endurance & Agility in Prepubertal Boys With Short Stature.","authors":"Ashish Malpani, Lurah Welch, Daniel Plummer, James Churilla, Matthew Benson, Jobayer Hossain, Joseph Permuy, Mauri Carakushansky, Nelly Mauras","doi":"10.1210/clinem/dgaf203","DOIUrl":"https://doi.org/10.1210/clinem/dgaf203","url":null,"abstract":"<p><strong>Context: </strong>Growth Hormone (GH) enhances muscle strength and aerobic capacity in adults with GH deficiency, but GH effects in skeletal muscle are less well characterized in youth.</p><p><strong>Objectives: </strong>To investigate the impact of GH on skeletal muscle in boys with significant short stature (SS) compared to age-matched, normally growing controls.</p><p><strong>Design: </strong>Open-label comparator.</p><p><strong>Setting: </strong>Outpatient endocrine clinic.</p><p><strong>Participants: </strong>45 prepubertal boys, SS, N = 30 (isolated GH deficiency or idiopathic SS) (mean(SE) age: 8.9 ± 0.3yrs; Height SDS:-2.3 ± 0.1); controls, N = 15 (8.8 ± 0.4yrs; HT SDS:-0.3 ± 0.2).</p><p><strong>Intervention: </strong>Anthropometry, fat-free-mass, resting energy expenditure (REE) and muscle testing was performed at baseline, 6 and 12-months after daily GH (SS group) or observation (controls).</p><p><strong>Main outcomes: </strong>Skeletal muscle strength (isometric dynamometry (flexion/extension) upper and lower extremities) (principal), power (vertical jump), endurance (modified push-ups), and agility (timed shuttle-runs); fat-free-mass accrual, and REE (secondary).</p><p><strong>Results: </strong>At baseline, the SS group had lower muscle strength in upper body (p≤0.027) and lower body (p≤0.007) vs. controls; similar lower body muscle power and agility; but lower endurance (p = 0.048). Baseline differences were significantly less after GH treatment, values in SS kids approaching those of controls by 12-months. Adjusting for height SDS and fat-free-mass between groups decreases detected differences in upper extremity muscle strength and endurance, but lower extremity muscle strength differences persist. No differences in REE were detected.</p><p><strong>Conclusions: </strong>Boys with significant SS have quantifiable deficits in upper and lower body skeletal muscle strength, and lower physical endurance compared to normally statured controls. GH treatment for 12-months can improve these metrics in prepubertal boys with SS.</p>","PeriodicalId":50238,"journal":{"name":"Journal of Clinical Endocrinology & Metabolism","volume":" ","pages":""},"PeriodicalIF":5.0,"publicationDate":"2025-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143765696","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}